{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:33Z","timestamp":1791078933284,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[1996,8,1]],"date-time":"1996-08-01T00:00:00Z","timestamp":838857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[1996,8]]},"DOI":"10.1007\/bf02505252","type":"journal-article","created":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T12:34:11Z","timestamp":1160570051000},"page":"543-548","source":"Crossref","is-referenced-by-count":32,"title":["Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA"],"prefix":"10.1007","volume":"288","author":[{"given":"G. P.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Seifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Pr\u00fcmmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. I.","family":"Joller-Jemelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02505252_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jir.1993.13.121","volume":"13","author":"CM Brand","year":"1993","unstructured":"Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G (1993) Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J Interferon Res 13: 121\u2013125","journal-title":"J Interferon Res"},{"key":"BF02505252_CR2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","volume":"121","author":"PJ Bunn","year":"1994","unstructured":"Bunn PJ, Hoffman SJ, Norris D, Golitz LE, Aeling JL (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121: 592\u2013602","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"BF02505252_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0168-8278(90)90156-L","volume":"11","author":"F Dianzani","year":"1990","unstructured":"Dianzani F, Antonelli G, Capobianchi MR (1990) The biological basis for clinical use of interferon. J Hepatol 11 [Suppl 1]: S5\u201310","journal-title":"J Hepatol"},{"key":"BF02505252_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/stem.5530110403","volume":"11","author":"B Dreno","year":"1993","unstructured":"Dreno B (1993) Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells (Dayt) 11: 269\u2013275","journal-title":"Stem Cells (Dayt)"},{"key":"BF02505252_CR5","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/1097-0142(19910501)67:9<2300::AID-CNCR2820670916>3.0.CO;2-A","volume":"67","author":"R Dummer","year":"1991","unstructured":"Dummer R, M\u00fcller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G (1991) Formation of neutralizing antibodies against natural interferon-\u03b2, but not against interferon-\u03b3 during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67: 2300\u20132304","journal-title":"Cancer"},{"key":"BF02505252_CR6","first-page":"135","volume":"1","author":"R Dummer","year":"1991","unstructured":"Dummer R, Nestle F, Wiede J, Sch\u00e4fer E, R\u00f6ger J, Erhard H, Hefner H, Burg G (1991) Coincidence of increased soluble interleukin-2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T-cell lymphomas. Eur J Dermatol 1: 135\u2013138","journal-title":"Eur J Dermatol"},{"key":"BF02505252_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.1993.01680250045005","volume":"129","author":"R Dummer","year":"1993","unstructured":"Dummer R, Kohl O, Gillisson J, K\u00e4gi M, Burg G (1993) Peripheral blood mononuclear cells in non-leukemic cutaneous T-cell lymphoma patients: reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation. Arch Dermatol 129: 433\u2013436","journal-title":"Arch Dermatol"},{"key":"BF02505252_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0190-9622(80)80385-9","volume":"2","author":"RL Edelson","year":"1980","unstructured":"Edelson RL (1980) Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 2: 89\u2013106","journal-title":"J Am Acad Dermatol"},{"key":"BF02505252_CR9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/10408369209114604","volume":"29","author":"D Fuchs","year":"1992","unstructured":"Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29: 307\u2013341","journal-title":"Crit Rev Clin Lab Sci"},{"key":"BF02505252_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2133.1993.tb03307.x","volume":"129","author":"JW Gilmour","year":"1993","unstructured":"Gilmour JW, Vestey JP, Norval M (1993) The effect of UV therapy on immune function in patients with psoriasis. Br J Dermatol 129: 28\u201338","journal-title":"Br J Dermatol"},{"key":"BF02505252_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","volume":"24","author":"RM Knobler","year":"1991","unstructured":"Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M (1991) Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 24: 247\u2013252","journal-title":"J Am Acad Dermatol"},{"key":"BF02505252_CR12","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1991.9.7.1298","volume":"9","author":"TM Kuzel","year":"1991","unstructured":"Kuzel TM, Roenigk HJ, Rosen ST (1991) Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis, and therapy, J Clin Oncol 9: 1298\u20131313","journal-title":"J Clin Oncol"},{"key":"BF02505252_CR13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jnci\/84.2.119","volume":"84","author":"TM Kuzel","year":"1992","unstructured":"Kuzel TM, Roenigk HJ, Samuelson E, Rosen ST (1992) Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst 84: 119\u2013121","journal-title":"J Natl Cancer Inst"},{"key":"BF02505252_CR14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jlb.54.2.138","volume":"54","author":"JD Laskin","year":"1993","unstructured":"Laskin JD, Mermelstein FH, Heindel ND, Ron Y (1993) Selective inactivation of lymphocytes after psoralen\/ultraviolet light (PUVA) treatment without affecting systemic immune responses. J Leukoc Biol 54: 138\u2013144","journal-title":"J Leukoc Biol"},{"key":"BF02505252_CR15","first-page":"18","volume":"14","author":"RD Leavitt","year":"1987","unstructured":"Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlock C, Myers JW, Kisner D, Norred S, Spiegel RJ, Bonnem EM (1987) Alta-2b interferon in the treatment of Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Semin Oncol 14: 18\u201323","journal-title":"Semin Oncol"},{"key":"BF02505252_CR16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archderm.1993.01680270085011","volume":"129","author":"EN Mostow","year":"1993","unstructured":"Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD (1993) Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 129: 747\u2013752","journal-title":"Arch Dermatol"},{"key":"BF02505252_CR17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jnci\/81.7.531","volume":"81","author":"K Oberg","year":"1989","unstructured":"Oberg K (1989) Antibodies in carcinoid syndrome. J Natl Cancer Inst 81: 531\u2013535","journal-title":"J Natl Cancer Inst"},{"key":"BF02505252_CR18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.1991.tb08119.x","volume":"48","author":"G Papa","year":"1991","unstructured":"Papa G, Tura S, Mandelli F, Vegna ML, Defazio D, Mazza P, Zinzani PL, Simoni R, DePita O, Ferranti G, et al (1991) Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 48: 48\u201351","journal-title":"Br J Haematol"},{"key":"BF02505252_CR19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0167-5699(94)90170-8","volume":"15","author":"M Peakman","year":"1994","unstructured":"Peakman M Vergani D (1994) Autoimmune disease: etiology, therapy and regeneration. Immunol Today 15: 345\u2013347","journal-title":"Immunol Today"},{"key":"BF02505252_CR20","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/1097-0142(19930301)71:5<1828::AID-CNCR2820710518>3.0.CO;2-0","volume":"71","author":"O Prummer","year":"1993","unstructured":"Prummer O (1993) Interferon-alpha antibodies in patients with reanl cell carcinoma treated with recombinant interferon-alpha 2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 71: 1828\u20131834.","journal-title":"Cancer"},{"key":"BF02505252_CR21","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.1985.3.11.1522","volume":"3","author":"JR Quesada","year":"1985","unstructured":"Quesada JR, Rios A, Swanson D, Tworn P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522\u20131528","journal-title":"J Clin Oncol"},{"key":"BF02505252_CR22","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","volume":"95","author":"H Roenigk","year":"1990","unstructured":"Roenigk H, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PJ, et al (1990) Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95: 198S-205S","journal-title":"J Invest Dermatol"},{"key":"BF02505252_CR23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000236199","volume":"98","author":"S Romagnani","year":"1992","unstructured":"Romagnani S (1992) Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98: 279\u2013285","journal-title":"Int Arch Allergy Immunol"},{"key":"BF02505252_CR24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198806023182201","volume":"318","author":"RG Steis","year":"1988","unstructured":"Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318: 1409\u20131413","journal-title":"N Engl J Med"},{"key":"BF02505252_CR25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(87)93034-0","volume":"2","author":"P Wussow von","year":"1987","unstructured":"Wussow P von, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (letter). Lancet 2: 635\u2013636","journal-title":"Lancet"},{"issue":"Suppl","key":"BF02505252_CR26","first-page":"25","volume":"9","author":"P Wussow von","year":"1989","unstructured":"Wussow P von, Jakschies D, Freund M, Deicher H (1989) Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J Interferon Res 9 [Suppl]: S25\u201331","journal-title":"J Interferon Res"},{"key":"BF02505252_CR27","doi-asserted-by":"crossref","first-page":"206S","DOI":"10.1111\/1523-1747.ep12875616","volume":"95","author":"H Zachariae","year":"1990","unstructured":"Zachariae H, Thestrup-Pedersen K (1990) Inteferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95: 206S-208S","journal-title":"J Invest Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02505252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02505252\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02505252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T13:49:56Z","timestamp":1558187396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02505252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1996,8]]}},"alternative-id":["BF02505252"],"URL":"https:\/\/doi.org\/10.1007\/bf02505252","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,8]]}}}